Prelude Therapeutics Income Statement (2024-2025) | PRLD

Income Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 3.00M4.00M6.50M
Operating items
Research & Development 29.46M31.62M21.71M
Selling, General & Administrative 7.92M6.21M5.21M
Operating Expenses 37.38M37.83M26.92M
Operating Income -34.38M-33.83M-20.42M
EBIT -34.38M-33.83M-20.42M
Non-operating items
Other Non Operating Income 2.10M5.10M0.69M
Non Operating Income 2.10M5.10M0.69M
Net income details
EBT -34.38M-33.83M-20.42M
Profit After Tax -32.27M-28.73M-19.73M
Income from Continuing Operations -34.38M-33.83M-20.42M
Consolidated Net Income -34.38M-33.83M-20.42M
Income towards Parent Company -34.38M-33.83M-20.42M
Net Income towards Common Stockholders -34.38M-33.83M-20.42M
Additional items
EPS (Basic) -0.43-0.38-0.26
EPS (Weighted Average and Diluted) -0.43-0.38-0.26
Shares Outstanding (Weighted Average) 54.92M54.93M55.02M55.04M55.15M56.46M56.60M
Shares Outstanding (Diluted Average) 75.74M75.76M75.86M75.81M75.99M75.99M76.13M
EBITDA -31.81M-28.86M-19.72M